PerspectiveCancer
Resistance to MEK Inhibitors: Should We Co-Target Upstream?
- 1Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
- 2Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
- 3Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
- ↵*Corresponding author. Telephone, 646-888-2641; e-mail, solitd{at}mskcc.org
See allHide authors and affiliations
Science Signaling 29 Mar 2011:
Vol. 4, Issue 166, pp. pe16
DOI: 10.1126/scisignal.2001948
Vol. 4, Issue 166, pp. pe16
DOI: 10.1126/scisignal.2001948
Poulikos I. Poulikakos
1Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
David B. Solit
2Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
3Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.